DGIdb - BUSULFAN Drug Record

BUSULFAN chembl:CHEMBL820 ApprovedAntineoplasticImmunotherapy

Alternate Names:

BUSULFEX
BUSILVEX
NCI-C01592
SULPHABUTIN
MYLERAN
BUSULFAN
NSC-750
MYELOSAN
1,4-DIMESYLOXYBUTANE
1,4-BIS(METHANESULFONOXY)BUTANE
MYLERAN®
BUSULFEX IV®
TETRAMETHYLENE BIS(METHANESULFONATE)
1,4-DIMETHANESULFONOXYBUTANE
1,4-BUTANEDIOL DIMETHANESULFONATE
pubchem.compound:2478
chembl:CHEMBL820
chemidplus:55-98-1
drugbank:01008
rxcui:1828

Drug Info:

(2 More Sources)

Publications:

Huezo-Diaz Curtis P et al., 2018, Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation., Pharmacogenomics J
Jabado et al., 1997, Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors., Blood
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Yee SW et al., 2013, Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia., J Hum Genet
Yeager et al., 1993, Hematopoietic cell transplantation in the twitcher mouse. The effects of pretransplant conditioning with graded doses of busulfan., Transplantation
Yeager et al., 1991, Hematopoietic cell transplantation after administration of high-dose busulfan in murine globoid cell leukodystrophy (the twitcher mouse)., Pediatr. Res.
Kuter et al., 1995, The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit., Blood
Cherian et al., 1989, Effect of busulfan on crystalline lens--glutathione, glutathione reductase and glucose-6-phosphate dehydrogenase., Indian J. Exp. Biol.
Uppugunduri CR et al., 2014, The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation., Pharmacogenomics J
ten Brink MH et al., 2013, Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation., Pharmacogenomics
Singh et al., 1983, Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells., Environ Mutagen
Harkey et al., 2005, Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan., Cancer Invest.

BUSULFAN GALC

Interaction Score: 10.91

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8101401 2034480

Sources:
NCI
BUSULFAN CTH

Interaction Score: 3.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27779248

Sources:
PharmGKB
BUSULFAN ADK

Interaction Score: 1.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6317371

Sources:
NCI
BUSULFAN GSTA1

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24192117

Sources:
PharmGKB
BUSULFAN BCR

Interaction Score: 0.61

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA
BUSULFAN ITGAL

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9389690

Sources:
NCI
BUSULFAN GSTM1

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23677058

Sources:
PharmGKB
BUSULFAN GSTP1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15779864

Sources:
NCI PharmGKB
BUSULFAN CYP2B6

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24165757

Sources:
PharmGKB
BUSULFAN ABL1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA
BUSULFAN G6PD

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2635153

Sources:
NCI
BUSULFAN THPO

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7742532

Sources:
NCI
BUSULFAN CYP2C19

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 24192117 24165757

Sources:
DTC PharmGKB
BUSULFAN CYP2C9

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24165757 22931300

Sources:
DTC PharmGKB
BUSULFAN CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
BUSULFAN CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
BUSULFAN CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

NCI: BUSULFAN

Version: 14-September-2017

Alternate Names:

C321 NCI drug code

Drug Info:

Publications:

Jabado et al., 1997, Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors., Blood

Singh et al., 1983, Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells., Environ Mutagen

Harkey et al., 2005, Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan., Cancer Invest.

DTC: BUSULFAN
- Version: 02-September-2020
Alternate Names:

CHEMBL820 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: busulfan

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Huezo-Diaz Curtis P et al., 2018, Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation., Pharmacogenomics J

ten Brink MH et al., 2013, Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation., Pharmacogenomics

Uppugunduri CR et al., 2014, The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation., Pharmacogenomics J

TTD: Busulfan
- Version: 2020.06.01
Alternate Names:

D07SUG TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL820
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Busulfan
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

BUSULFAN Drug Record

BUSULFAN chembl:CHEMBL820 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8101401 2034480

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27779248

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6317371

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24192117

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Fusion protein BCR:ABL1

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9389690

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23677058

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15779864

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24165757

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Fusion protein BCR:ABL1

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2635153

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7742532

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300 24192117 24165757

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24165757 22931300

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

NCI: BUSULFAN

Alternate Names: C321 NCI drug code

Drug Info:

DTC: BUSULFAN

Alternate Names: CHEMBL820 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

PMIDs:
8101401 2034480

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27779248

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
6317371

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
24192117

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
9389690

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23677058

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15779864

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24165757

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
2635153

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7742532

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22931300 24192117 24165757

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24165757 22931300

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

C321 NCI drug code

Alternate Names:

CHEMBL820 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

D07SUG TTD Drug ID